CELU

Celularity to Present Data Showing Senescent Cell Elimination by Off-the-Shelf Natural Killer Cells Derived from Human Placental Cells

Retrieved on: 
Monday, April 8, 2024
CELU, Notifiable disease, Cell, Inflammation, Tissue, Gene, Cancer, SASP, Ageing, Society, Heart, NK, Annual general meeting, Vaccine

The preclinical data, which suggest that Celularity’s placenta-derived unmodified natural killer (NK) cells (CYNK-001) and genetically modified NK cells (CYNK-201) may serve as potent and selective senolytic agents for use in addressing age-related diseases, will be presented on May 9, 2024.

Key Points: 
  • The preclinical data, which suggest that Celularity’s placenta-derived unmodified natural killer (NK) cells (CYNK-001) and genetically modified NK cells (CYNK-201) may serve as potent and selective senolytic agents for use in addressing age-related diseases, will be presented on May 9, 2024.
  • Senescent cells are key drivers in the process of age-related cellular corruption at the heart of degenerative diseases, cancer and immuno-senescence (the progressive decline in immune function that occurs with age).
  • Moreover, if not eliminated, these cells impair the normal regenerative process that restores function to organs and tissues.
  • Celularity believes these preclinical data demonstrate the potential of its assets to target and selectively remove damaged and abnormal cells expressing stress ligands, such as senescent, virally infected and cancer cells.

Celularity Receives Healthcare Common Procedure Coding System (HCPCS) Q Code Approval from the U.S. Centers for Medicare & Medicaid Services for Biovance® 3L

Retrieved on: 
Tuesday, March 26, 2024
CELU, HCPCS, Growth, Regenerative medicine, Medicare, CMS

The designated HCPCS Q code is Q4283 and is available starting April 1, 2024.

Key Points: 
  • The designated HCPCS Q code is Q4283 and is available starting April 1, 2024.
  • "The HCPCS Q code approval by CMS further recognizes Biovance® 3L as an important therapeutic option for the treatment of wounds,” said Dr. Robert J. Hariri, M.D., Ph.D., Celularity CEO, chairman and founder.
  • “The medical community has been rapidly adopting this product, and the HCPCS Q code approval paves the way for Biovance® 3L to realize additional growth, enabling the potential to impact more lives.
  • We will continue to innovate in this important part of our business and look forward to providing future updates.”
    The Healthcare Common Procedure Coding System (HCPCS) is produced by the Centers for Medicare and Medicaid Services (CMS).

Kuehn Law Encourages Investors of Celularity Inc. to Contact Law Firm

Retrieved on: 
Friday, March 22, 2024
CELU, PLLC, Human

NEW YORK, March 22, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Celularity, Inc. (NASDAQ: CELU) breached their fiduciary duties to shareholders.

Key Points: 
  • NEW YORK, March 22, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Celularity, Inc. (NASDAQ: CELU) breached their fiduciary duties to shareholders.
  • Kuehn Law pays all case costs and does not charge its investor clients.
  • Shareholders should contact the firm immediately as there may be limited time to enforce your rights.
  • As a shareholder your voice matters, and by getting involved, you contribute to the integrity and fairness of the financial markets.

Celularity Submits Request to U.S. FDA for Orphan Drug Designation for PDA-002 Asset Treating Facioscapulohumeral Muscular Dystrophy

Retrieved on: 
Wednesday, March 20, 2024
CELU, Diagnosis, Shoulder, Biologics license application, Disease, Risk, Patient, Microsoft Exchange Server, Stem cell, IND, Facioscapulohumeral muscular dystrophy, Regenerative medicine, FDA, BLA, FSHD, Muscular dystrophy, Food, Pharmaceutical industry

FLORHAM PARK, N.J., March 20, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ: CELU) (“Celularity”), a regenerative medicine company developing placental-derived allogeneic cell therapies and advanced biomaterial products, announced today that it has submitted a request to the U.S. Food and Drug Administration (FDA) for orphan drug designation for its off-the-shelf, placental-derived cell therapy, PDA-002, for treating Facioscapulohumeral Muscular Dystrophy (FSHD).

Key Points: 
  • FLORHAM PARK, N.J., March 20, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ: CELU) (“Celularity”), a regenerative medicine company developing placental-derived allogeneic cell therapies and advanced biomaterial products, announced today that it has submitted a request to the U.S. Food and Drug Administration (FDA) for orphan drug designation for its off-the-shelf, placental-derived cell therapy, PDA-002, for treating Facioscapulohumeral Muscular Dystrophy (FSHD).
  • Orphan drug designation is a status given to drugs that show the potential to treat, prevent or diagnose serious or life-threatening diseases that affect fewer than 200,000 people in the U.S.
  • Earlier, Celularity received FDA Investigational New Drug Application clearance for PDA-002 in FSHD and plans to commence a phase 1/2 study in the second half of 2024.
  • The trial serves as an important component for submitting a Biologics License Application (BLA) to the FDA in the future as a potential treatment for FSHD and other types of muscular dystrophy.

Celularity CEO to Present on Cell Therapy’s Potential to Improve Longevity at 2024 ABUNDANCE Summit

Retrieved on: 
Thursday, March 14, 2024
CELU, Cell, Tissue, Research, Sarcopenia, Cornell University, Cancer, Biology, Pulse, Regenerative medicine, Immunity, Placenta, Singularity Group, Immunosenescence, Movement, Autoimmunity, Ageing, Medicine

Dr. Hariri’s presentation, titled “The Cell Therapy Basis for Longevity,” will discuss the potential for using cellular therapeutics to address the biological ravages of aging by combating immunosenescence, sarcopenia and degenerative diseases.

Key Points: 
  • Dr. Hariri’s presentation, titled “The Cell Therapy Basis for Longevity,” will discuss the potential for using cellular therapeutics to address the biological ravages of aging by combating immunosenescence, sarcopenia and degenerative diseases.
  • Dr. Hariri has led the effort to harness the unique biology of placental-derived cells in a range of clinical indications, including cancer, autoimmune and degenerative diseases.
  • “Dr.
  • This work puts Dr. Hariri at the forefront of the longevity movement, with his finger on the pulse of the ever-changing landscape.”
    The ABUNDANCE Summit will occur in Los Angeles, Calif., from March 17 through 21, 2024.

Celularity CEO to Present Keynote Address at 2024 Society for Brain Mapping and Therapeutics Annual World Congress

Retrieved on: 
Tuesday, March 12, 2024
CELU, Annual, Weill Cornell Medicine, Medical device, SBMT, Congress, Dementia, Innovation Park, Brain mapping, WBMF, Multiple sclerosis, Immunotherapy, Patient, Brain, Nanotechnology, Cancer, AI, Cell therapy, Society, Neurosurgery, Regenerative medicine, Therapy, DSM-IV codes, Cell, Virtual reality, Pharmaceutical industry

FLORHAM PARK, N.J., March 12, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ: CELU) (“Celularity” or the “Company”), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, announced today that the Company’s Founder and CEO, Dr. Robert Hariri, M.D., Ph.D., will present the keynote lecture at the Society for Brain Mapping and Therapeutics (SBMT) Annual World Congress on March 16, 2024.

Key Points: 
  • FLORHAM PARK, N.J., March 12, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ: CELU) (“Celularity” or the “Company”), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, announced today that the Company’s Founder and CEO, Dr. Robert Hariri, M.D., Ph.D., will present the keynote lecture at the Society for Brain Mapping and Therapeutics (SBMT) Annual World Congress on March 16, 2024.
  • Dr. Hariri’s keynote, titled, “Future of Cell and Immunotherapy – Cancer to Neurodegenerative Disorders,” will address cellular immunotherapy’s broad applications beyond cancer, including its potential use in neuroinflammatory and degenerative conditions, such as multiple sclerosis and Parkinson’s disease.
  • Celularity is advancing innovative cellular therapeutics to treat a range of diseases, including neurologic diseases from brain cancer to age-related cognitive decline.
  • SBMT’s 21st Annual World Congress will take place in Los Angeles, Calif., on March 14 through 17, 2024.

Celularity to Present Data Showing Cancer Tumor Reduction by Off-the-Shelf Cell Therapy Derived from Human Placental Cells

Retrieved on: 
Thursday, March 7, 2024
Cancer, Stem cell, Cell, Antibody, Stomach, Trastuzumab, NK, CELU, Microsoft Exchange Server, Medical imaging

These data, which highlight the platform’s robust anti-tumor activity against gastric cancer will be presented on April 9th, 2024.

Key Points: 
  • These data, which highlight the platform’s robust anti-tumor activity against gastric cancer will be presented on April 9th, 2024.
  • Celularity is developing a platform to combine a broad portfolio of cell therapies with various approved antibodies to address multiple cancers and other conditions.
  • Celularity’s preclinical asset, PT-CD16VS, is initially being developed in combination with trastuzumab, a cancer drug, for treating HER2-positive cancers.
  • “These data demonstrate the promise and potential of combining Celularity’s cell therapy assets with currently available therapies to address difficult-to-treat cancers,” said Dr. Robert Hariri, Celularity’s CEO and Founder.

Celularity Announces 1-for-10 Reverse Stock Split

Retrieved on: 
Friday, February 23, 2024
Transfer, Common stock, Exercise, Common, CUSIP, Trust, CELU, Security (finance)

Accordingly, the public and private warrants that are currently traded under the ticker symbol “CELUW” will be proportionally adjusted such that every 10 shares of Common Stock that may be purchased pursuant to the warrants immediately prior to the reverse stock split now represent one share of Common Stock that may be purchased immediately following the reverse stock split.

Key Points: 
  • Accordingly, the public and private warrants that are currently traded under the ticker symbol “CELUW” will be proportionally adjusted such that every 10 shares of Common Stock that may be purchased pursuant to the warrants immediately prior to the reverse stock split now represent one share of Common Stock that may be purchased immediately following the reverse stock split.
  • Correspondingly, the exercise price per share of Class A common stock attributable to such warrants immediately prior to the reverse stock split has been proportionately increased, such that the exercise price immediately following the reverse stock split is $115.
  • Continental Stock Transfer and Trust, Celularity’s transfer agent, will act as the exchange agent for the reverse stock split.
  • In connection with the reverse stock split, the CUSIP number for Celularity’s post-split Class A common stock will change to 151190 204.

Celularity’s Tri-layer Decellularized, Dehydrated Human Amniotic Membrane Product Investigated as a Carrier of Induced Pluripotent Stem Cell Derived-Limbal Stem Cells in the Treatment of Severe Ocular Surface Disease

Retrieved on: 
Wednesday, February 14, 2024
Engineering, Regeneration, Regenerative medicine, Inflammation, North Carolina State University, Neovascularization, Infection, South Korea, WBC, Wilson College, Tissue engineering, KSBM, Decellularization, Congress, CELU, Trauma, Tissue, Development, Culture of Korea, LSC, Wound healing

FLORHAM PARK, N.J., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”) a biotechnology company developing allogeneic cell therapies and advanced biomaterial products, today announced that its abstract “Tri-layer decellularized, dehydrated human amniotic membrane supports proliferation and stemness of limbal stem cells derived from induced pluripotent stem cells” has been accepted as a poster presentation at WBC 2024, the 12th World Biomaterials Congress which will be held on 26-31 May 2024 in Daegu, Republic of Korea, and hosted by the Korean Society for Biomaterials (KSBM). The theme of WBC 2024 is “Convergence in Biomaterials: a vision for the future of healthcare.”

Key Points: 
  • The theme of WBC 2024 is “Convergence in Biomaterials: a vision for the future of healthcare.”
    The study described in the poster presentation investigated Celularity’s tri-layer decellularized, dehydrated human amniotic membrane technology product as a carrier of induced pluripotent stem cell derived-limbal stem cells (iPSC-LSC) which were investigated for the treatment of limbal stem cell deficiency (LSCD).
  • Limbal Stem Cell (LSC) transplant is a recognized method to restore the ocular surface in advanced stem cell deficient corneas.
  • Its Tissue Engineering Lab Team is particularly interested in corneal tissue engineering, focusing primarily on ocular surface regeneration.
  • The off-the-shelf availability of existing commercial tri-layer decellularized, dehydrated human amniotic membrane products, in combination with iPSC-LSCs, may improve patient access to LSCD treatment and the therapeutic management of LSCD.

Celularity Announces Net Sales Expectations for First Quarter 2024 and Full Year 2024, Reiterates Advanced Biomaterial Product Commercial and Development Pipeline

Retrieved on: 
Thursday, February 1, 2024
Traction, Growth, Umbilical cord, Extracellular matrix, Extremities, Regenerative medicine, Chronic pain, Combination, Collagen, Pelvis, CELU, Cytokine, Knee, Environment, Exosome, FDA, Disorder, Osteoarthritis, Device, Food, Decellularization, Dentistry, Protein, Disability, Chemokine, Sale, Tissue, GMP, Burns, Pharmaceutical industry

FLORHAM PARK, N.J., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the “Company”) a biotechnology company developing allogeneic cell therapies and advanced biomaterial products, today announced expected net sales of its biomaterial products and biobanking businesses for the first quarter 2024 and the full year 2024, respectively, and reiterated its previously disclosed advanced biomaterial product commercial and development pipeline. As used here, “net sales” refers exclusively to revenue from the sale of advanced biomaterial products and biobanking services, respectively, and does not include any revenue from other sources such as license fees and royalties or revenue earned under research collaboration agreements.

Key Points: 
  • FLORHAM PARK, N.J., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the “Company”) a biotechnology company developing allogeneic cell therapies and advanced biomaterial products, today announced expected net sales of its biomaterial products and biobanking businesses for the first quarter 2024 and the full year 2024, respectively, and reiterated its previously disclosed advanced biomaterial product commercial and development pipeline.
  • “Our sales of advanced biomaterial products grew dramatically in the fourth quarter of 2023 as our newest Biovance 3L product gained traction.
  • The Company expects in future to update expected full year 2024 net sales of its advanced biomaterial product and biobanking businesses.
  • The Company’s advanced biomaterial product pipeline consists of four commercial-stage products and three development-stage product candidates.